TY - JOUR
T1 - A case of pancreatic cancer with local recurrence and liver metastases eight years after surgery
AU - Taniguchi, Hajime
AU - Mizuma, Masamichi
AU - Motoi, Fuyuhiko
AU - Abe, Tomoya
AU - Okada, Ryo
AU - Kawaguchi, Kei
AU - Karasawa, Hideaki
AU - Masuda, Kunihiro
AU - Yabuuchi, Shinichi
AU - Fukase, Koji
AU - Sakata, Naoaki
AU - Okada, Takaho
AU - Nakagawa, Kei
AU - Hayashi, Hiroki
AU - Morikawa, Takanori
AU - Yoshida, Hiroshi
AU - Naito, Takeshi
AU - Katayose, Yu
AU - Egawa, Shinichi
AU - Unno, Michiaki
PY - 2014/11
Y1 - 2014/11
N2 - Here we report a rare case of late recurrence of pancreatic cancer 8 years after surgery. A woman in her mid-fifties was hopitalized for examination of epigastralgia. Computed tomography (CT) revealed a 4 cm nodule at the pancreatic head with suspected invasion of the superior mesenteric vein. She underwent pancreaticoduodenectomy with wedge resection of superior mesenteric vein and intraoperative radiation therapy. Pathological findings showed moderately differentiated tubular adenocarcinoma and T3N1 MO, Stage II B according to The Union for International Cancer Control (UICC) TNM classification. As adjuvant chemotherapy, 56 courses of gemcitabine (GEM) were administered in 3.5 years. Because of long-term use of GEM, common terminology criteria for adverse events (CTCAE) Grade 3 anemia occurred, and chemotherapy was discontinued. Tumor markers were evaluated every month and CT scans were taken every 6 months for 5 years. Subsequently, CT was performed annually. The patient was hospitalized for high-grade fever, 8.5 years after surgery. CT, magnetic resonance imaging (MRI) and positron emission tomography-computed tomography (PET-CT) detected local recurrence with liver metastases. GEM was administered again, but was ineffective. The patient died 9 years after surgery. In conclusion, even if long-term survival is achieved in pancreatic cancer, follow-ups should not be stopped.
AB - Here we report a rare case of late recurrence of pancreatic cancer 8 years after surgery. A woman in her mid-fifties was hopitalized for examination of epigastralgia. Computed tomography (CT) revealed a 4 cm nodule at the pancreatic head with suspected invasion of the superior mesenteric vein. She underwent pancreaticoduodenectomy with wedge resection of superior mesenteric vein and intraoperative radiation therapy. Pathological findings showed moderately differentiated tubular adenocarcinoma and T3N1 MO, Stage II B according to The Union for International Cancer Control (UICC) TNM classification. As adjuvant chemotherapy, 56 courses of gemcitabine (GEM) were administered in 3.5 years. Because of long-term use of GEM, common terminology criteria for adverse events (CTCAE) Grade 3 anemia occurred, and chemotherapy was discontinued. Tumor markers were evaluated every month and CT scans were taken every 6 months for 5 years. Subsequently, CT was performed annually. The patient was hospitalized for high-grade fever, 8.5 years after surgery. CT, magnetic resonance imaging (MRI) and positron emission tomography-computed tomography (PET-CT) detected local recurrence with liver metastases. GEM was administered again, but was ineffective. The patient died 9 years after surgery. In conclusion, even if long-term survival is achieved in pancreatic cancer, follow-ups should not be stopped.
KW - Late recurrence
KW - Pancreatic cancer
UR - http://www.scopus.com/inward/record.url?scp=84949235100&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84949235100&partnerID=8YFLogxK
M3 - Article
C2 - 25731467
AN - SCOPUS:84949235100
SN - 0385-0684
VL - 41
SP - 2193
EP - 2195
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
IS - 12
ER -